New drug cocktail aims to reverse fatty liver damage in diabetics

NCT ID NCT07303803

Recruiting now Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called chiglitazar, combined with anti-inflammatory and liver-protecting therapies, can improve liver health in people who have both MASH (a severe fatty liver disease) and type 2 diabetes. About 300 adults will receive either the drug combo or a placebo for several months. The main goal is to see if the treatment can resolve liver inflammation without worsening scarring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Chiglitazar (a drug that targets metabolism and inflammation), vitamin E, and polyene phosphatidylcholine
What this could lead to: If successful, this combination could offer a new treatment option for people with both MASH and type 2 diabetes, potentially reducing liver inflammation and scarring.
What could go wrong: This is an early Phase 2 trial with only 300 participants, so results may not apply to everyone. The treatment involves multiple drugs, which could increase side effects or interactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS T2DM (TYPE 2 DIABETES MELLITUS)

Contacts and locations

Locations

Ditan Hospital of integrated traditional Chinese and Western Medicine Center
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100015, China
Renji hospital of Shanghai Jiao Tong University School of Medical
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200001, China
Ruijin Hospital of Shanghai Jiaotong University School of Medicine
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200020, China
Shanghai Public Health Clinical Center
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200083, China
Shanghai Punan Hospital of Pudong New District (Punan Branch of Renji Hospital, Shanghai Jiaotong University School of Medicine)
RECRUITING

Shanghai, Shanghai Municipality, 200125, China
Southern Hospital
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510515, China
Southwest Hospital of Third Military Medical University
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, 400038, China
Taihe Hospital
NOT_YET_RECRUITING

Shiyan, Hubei, 442000, China
The First Affiliated Hospital of Fujian Medical University
NOT_YET_RECRUITING

Fuzhou, Fujian, 350005, China
The First Affiliated Hospital of Jilin University
NOT_YET_RECRUITING

Changchun, Jilin, 130021, China
The First Affiliated Hospital of Xi'an Jiao Tong University
NOT_YET_RECRUITING

Xi’an, Shanxi, 710061, China
The First Affiliated Hospital of Zhejiang University
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310003, China
The First Teaching Hospital of Xinjiang Medical University
NOT_YET_RECRUITING

Ürümqi, Xinjiang, 830054, China
The Third Affiliated Hospital of Sun Yat-sen University
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510000, China
Tianjin Second People's Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300192, China
Wuhan Union Hospital of Huazhong University of Science and Technology
NOT_YET_RECRUITING

Wuhan, Hebei, 430022, China
Xiangya hospital of Central South University
NOT_YET_RECRUITING

Changsha, Hunan, 410008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.